Home Daily Stock Opinions and Ratings Ishares Nasdaq Biotechnology (IBB-Q)

Trending stocks today

Cenovus Energy Headwater Exploration Inc. Mainstreet Equity Corp Parex Resources Inc. Visa Inc. Canadian Pacific Rail Canadian Natural Rsrcs Zscaler Inc. VMware Inc. PVH Corp Nike Inc Verizon Communications CCL Industries (B) Polo Ralph Lauren Corp. TJX Companies BMO EQUAL WEIGHT BANKS INDEX ETF ProShare Ultra Short 20+ yr Treasury ETF Monster Beverage Corp

Ishares Nasdaq Biotechnology (IBB-Q)

61 watching

NASDAQ:IBB

129.83
0.85 (0.66%) 1d
Jun 5, 2023, 4:55 pm
0
BUY

Ishares Nasdaq Biotechnology(IBB-Q)

28/10/2022
Ishares Nasdaq Biotechnology
The IBB has never had two down years in a row, except this and last year. It's having its best month since June 2021.
E.T.F.'s
Stephen Weiss, Founder, Short Hills Capital Partners
$128.090
Unknown
UnlockRating
BUY

Ishares Nasdaq Biotechnology(IBB-Q)

19/08/2022
Ishares Nasdaq Biotechnology
He likes biotech, focusing on longevity research. Better than owning a single biotech stock where you can lose 80% just on negative research findings. It's completely random--you have no idea what the outcome will be on these biotech products. Might as well own IBB and lessen risk.
E.T.F.'s
Kevin O'Leary
$128.335
Owned
UnlockRating
WATCH

Ishares Nasdaq Biotechnology(IBB-Q)

13/05/2022
Ishares Nasdaq Biotechnology
He sold IBB last month, though he owns a lot of Regeneron (for its fundamentals) in the biotech space. You need to own individual names, not the macro in biotechs. But he could re-enter IBB when the time is right.
E.T.F.'s
Rob Sechan, Managing Partner, New Edge Capital
$113.185
No
UnlockRating
DON'T BUY

Ishares Nasdaq Biotechnology(IBB-Q)

03/02/2022
Ishares Nasdaq Biotechnology
IBB vs. XLV XLV has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.
E.T.F.'s
Paul MacDonald
$130.960
No
UnlockRating
BUY ON WEAKNESS

Ishares Nasdaq Biotechnology(IBB-Q)

31/12/2021
Ishares Nasdaq Biotechnology
IBB gives him exposure to Moderna, its largest holding, and yet there's no single-company risk here. Biotechs have been under a lot of pressure this year, so he sees an opportunity (past of the pressure has been from shorting) if you're patient. He likes the future of biotech.
E.T.F.'s
Stephen Weiss, Founder, Short Hills Capital Partners
$153.745
Owned
UnlockRating
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

24/06/2021
Ishares Nasdaq Biotechnology
(A Top Pick Jul 09/20, Up 14%) Still likes it, but took profits as the valuation was getting expensive, plus the shift from growth to value. Long term, lots of tailwinds.
E.T.F.'s
Stan Wong
$161.700
No
UnlockRating
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

19/05/2021
Ishares Nasdaq Biotechnology
(A Top Pick Jul 09/20, Up 6%) Sold in February, as he saw the writing on the wall with the rotation away from growth. Not cheap at 28x. Long-term, makes a lot of sense. Aging population, growing middle class in emerging markets will keep demand up.
E.T.F.'s
Stan Wong
$148.780
No
UnlockRating
BUY

Ishares Nasdaq Biotechnology(IBB-Q)

13/07/2020
Ishares Nasdaq Biotechnology

Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

E.T.F.'s
John Zechner
$141.990
No
UnlockRating
TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

09/07/2020
Ishares Nasdaq Biotechnology
Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.
E.T.F.'s
Stan Wong
$140.055
Owned
UnlockRating
HOLD

Ishares Nasdaq Biotechnology(IBB-Q)

02/01/2020
Ishares Nasdaq Biotechnology
A very good biotech ETF. If you have it and you like it, stay with it. See what percentage of your portfolio it comprises. For a sector play, don't go above 5-6% of your portfolio. You want to invest in it, not day trade it with every move.
E.T.F.'s
John Hood
$119.890
Unknown
UnlockRating
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

18/10/2019
Ishares Nasdaq Biotechnology
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
E.T.F.'s
Hap (Robert) Sneddon FCSI
$102.270
Owned
UnlockRating
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

29/08/2019
Ishares Nasdaq Biotechnology
(A Top Pick Jun 20/19, Down 5%) A pick from his aggressive growth strategy, so you get more volatility. Sees support. If there's a 10% bump, then he'll sell.
E.T.F.'s
Keith Richards
$103.620
Owned
UnlockRating
TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

20/06/2019
Ishares Nasdaq Biotechnology
Not for everybody. This is for the more aggressive mandates. The expense ratio is 47 basis points. This is for rapid trading. He thinks it will get to the $115 target.
E.T.F.'s
Keith Richards
$108.620
Owned
UnlockRating
TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

07/06/2019
Ishares Nasdaq Biotechnology
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
E.T.F.'s
Hap (Robert) Sneddon FCSI
$103.830
Owned
UnlockRating
TOP PICK

Ishares Nasdaq Biotechnology(IBB-Q)

06/05/2019
Ishares Nasdaq Biotechnology
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
E.T.F.'s
Hap (Robert) Sneddon FCSI
$108.830
Owned
UnlockRating
Showing 1 to 15 of 73 entries
Next PageNext Page

Ishares Nasdaq Biotechnology(IBB-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 2

Stockchase rating for Ishares Nasdaq Biotechnology is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Ishares Nasdaq Biotechnology(IBB-Q) Frequently Asked Questions

What is Ishares Nasdaq Biotechnology stock symbol?

Ishares Nasdaq Biotechnology is a American stock, trading under the symbol IBB-Q on the NASDAQ (IBB). It is usually referred to as NASDAQ:IBB or IBB-Q

Is Ishares Nasdaq Biotechnology a buy or a sell?

In the last year, 2 stock analysts published opinions about IBB-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Ishares Nasdaq Biotechnology.

Is Ishares Nasdaq Biotechnology a good investment or a top pick?

Ishares Nasdaq Biotechnology was recommended as a Top Pick by on . Read the latest stock experts ratings for Ishares Nasdaq Biotechnology.

Why is Ishares Nasdaq Biotechnology stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Ishares Nasdaq Biotechnology worth watching?

2 stock analysts on Stockchase covered Ishares Nasdaq Biotechnology In the last year. It is a trending stock that is worth watching.

What is Ishares Nasdaq Biotechnology stock price?

On 2023-06-05, Ishares Nasdaq Biotechnology (IBB-Q) stock closed at a price of $129.83.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

AQN-TAlgonquin Power & Utilities Corp
Algonquin Power & Utilities Corp
$11.62
0.18 (1.53%)
FR-TFirst Majestic Silver
First Majestic Silver
$7.90
-0.04 (-0.51%)
BRK.B-NBerkshire Hathaway Inc. (B)
Berkshire Hathaway Inc. (B)
$328.58
-0.90 (-0.27%)
PLTR-NPalantir Technologies
Palantir Technologies
$15.24
0.72 (4.51%)
PANW-NPalo Alto Networks
Palo Alto Networks
$226.79
9.55 (4.04%)
Advertising

Today's Top Picks

MNST-QMonster Beverage Corp
Monster Beverage Corp
$59.57
0.09 (0.14%)
TBT-NProShare Ultra Short 20+ yr Treasury ETF
ProShare Ultra Short 20+ yr Treasury ETF
$30.10
0.62 (2.02%)
ZEB-TBMO EQUAL WEIGHT BANKS INDEX ETF
BMO EQUAL WEIGHT BANKS INDEX ETF
$32.75
-0.48 (-1.49%)
TJX-NTJX Companies
TJX Companies
$78.86
0.75 (0.94%)
RL-NPolo Ralph Lauren Corp.
Polo Ralph Lauren Corp.
$112.12
-0.46 (-0.41%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

META-QMeta Platforms Inc / Facebook
Meta Platforms Inc / Facebook
$271.39
-1.22 (-0.45%)
SNOW-NSnowflake
Snowflake
$181.75
6.54 (3.47%)
DG-NDollar General Corp.
Dollar General Corp.
$158.87
-7.25 (-4.78%)
DLTR-QDollar Tree
Dollar Tree
$133.05
-0.56 (-0.42%)
MMM-N3M Co.
3M Co.
$97.98
-4.55 (-4.87%)

Most Recent Experts

Berman

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Sneddon

Hap (Robert) Sneddon FCSI

Castlemoore Inc.

Stockchase

Stockchase Insights

5i Research

Cramer

Jim Cramer - Mad Money

CNBC

Gems

The Monthly Gems by Allan Tong

Stockchase

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.